174 related articles for article (PubMed ID: 16397368)
1. [Bisphosphonate or Raloxifene?: which drug we can choose for osteoporotic patients?].
Miki T; Saito S
Clin Calcium; 2006 Jan; 16(1):167-74. PubMed ID: 16397368
[TBL] [Abstract][Full Text] [Related]
2. [Daily practice using the guidelines for prevention and treatment of osteoporosis. Utilization of metabolic markers of bone in daily osteoporosis practice].
Miki T; Masaki H
Clin Calcium; 2008 Aug; 18(8):1127-34. PubMed ID: 18677050
[TBL] [Abstract][Full Text] [Related]
3. [Combination therapy for osteoporosis].
Kishimoto H
Nihon Rinsho; 2009 May; 67(5):975-9. PubMed ID: 19432119
[TBL] [Abstract][Full Text] [Related]
4. Compliance with drug therapies for the treatment and prevention of osteoporosis.
McCombs JS; Thiebaud P; McLaughlin-Miley C; Shi J
Maturitas; 2004 Jul; 48(3):271-87. PubMed ID: 15207894
[TBL] [Abstract][Full Text] [Related]
5. [Effects of SERMs on bone health. Effects of raloxifene and bisphosphonate on bone quality in osteoporosis: collagen cross-links, mineralization, and bone strength].
Saito M
Clin Calcium; 2010 Mar; 20(3):345-54. PubMed ID: 20190364
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of bone quality. Bone quality and osteoporosis treatment].
Mashiba T
Clin Calcium; 2008 Mar; 18(3):300-7. PubMed ID: 18310816
[TBL] [Abstract][Full Text] [Related]
7. [Bisphosphonate therapy for osteoporosis and bone strength].
Kishimoto H
Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477
[TBL] [Abstract][Full Text] [Related]
8. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
[No Abstract] [Full Text] [Related]
9. [Drug selection guide for osteoporosis determined by the clinical staging, pathophysiology and age].
Tanaka I; Oshima H
Nihon Rinsho; 2009 May; 67(5):915-20. PubMed ID: 19432109
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
11. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
Otrock ZK; Azar ST; Shamseddeen WA; Habr D; Inati A; Koussa S; Mahfouz RA; Taher AT
Ann Hematol; 2006 Sep; 85(9):605-9. PubMed ID: 16830143
[TBL] [Abstract][Full Text] [Related]
12. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Yamaguchi T; Sugimoto T
Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
[TBL] [Abstract][Full Text] [Related]
13. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
Cramer JA; Silverman S
Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
[TBL] [Abstract][Full Text] [Related]
14. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
15. [Adverse events of drugs for the treatment of osteoporosis].
Nakamura T
Nihon Rinsho; 2007 Oct; 65 Suppl 8():304-10. PubMed ID: 18074553
[No Abstract] [Full Text] [Related]
16. Bisphosphonate therapy and dental treatment.
Phillips G
J Indiana Dent Assoc; 2007-2008 Winter; 86(4):4-8. PubMed ID: 18363257
[No Abstract] [Full Text] [Related]
17. [Is SSBT associated with atypical femoral fracture? SSBT is associated with atypical femoral fracture - pathophysiology of atypical femoral fractures - ].
Mashiba T
Clin Calcium; 2012 Jun; 22(6):914-8. PubMed ID: 22653033
[TBL] [Abstract][Full Text] [Related]
18. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
Emkey RD; Ettinger M
Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
[TBL] [Abstract][Full Text] [Related]
19. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
20. Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene.
Stürmer EK; Seidlová-Wuttke D; Sehmisch S; Rack T; Wille J; Frosch KH; Wuttke W; Stürmer KM
J Bone Miner Res; 2006 Jan; 21(1):89-96. PubMed ID: 16355277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
